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ABSTRACT
Introduction Reductions in exacerbation and 
hospitalisations are the outcomes rated as most important by 
people with chronic obstructive pulmonary disease (COPD). 
Most COPD management is currently based on a reactive 
approach, and delays in recognising treatable opportunities 
underpin COPD care quality gaps. Innovations that empower 
COPD self- management, facilitate integrated clinical care and 
support delivery of evidence- based treatment interventions 
are urgently required.
Methods and analysis The Remote- Management of 
COPD: Evaluating the Implementation of Digital Innovation 
to Enable Routine Care trial is a prospective observational 
cohort hybrid implementation and effectiveness study 
that will explore the adoption of a digital service model for 
people with ‘high- risk’ COPD and evaluate the feasibility 
of this approach versus current standards of care. People 
with COPD, who have had recent severe exacerbation and/
or COPD–obstructive sleep apnoea overlap or chronic 
hypercapnic respiratory failure requiring home non- 
invasive ventilation (NIV) or continuous positive airway 
pressure (CPAP), with internet access will be recruited 
into the study and enrolled into the digital service.
Study endpoints will examine participant utilisation, 
clinical service impact and clinical outcomes compared 
with historical and contemporary control patient data. 
The digital infrastructure will also provide a foundation to 
explore the feasibility of approaches to predict outcomes 
and exacerbation in people with COPD through machine 
learning analysis.
Ethics and dissemination Ethical approval for this 
clinical trial has been obtained from the West of Scotland 
Research Ethics Service. The trial will commence in 
September 2019 for a duration of 2 years. Results will be 
presented at local, national and international meetings, 
as well as submission for publication to peer- reviewed 
journals.
Trial registration number NCT04240353.
INTRODUCTION
Chronic obstructive pulmonary disease 
(COPD) is a common, preventable and 
treatable disease, which is characterised by 
persistent respiratory symptoms and airflow 
limitation. The main risk factor for COPD 
is tobacco smoke but other environmental 
exposure may contribute. Respiratory symp-
toms include breathlessness, cough and/
or sputum production. These symptoms are 
under- reported by patients.1 2 COPD may be 
punctuated by periods of acute worsening of 
these respiratory symptoms, often referred to 
as exacerbation, that can result in emergency 
department (ED) attendance or hospital 
admission. For many patients, COPD is asso-
ciated with significant comorbidity, which 
increases its morbidity and mortality.
COPD is a major healthcare challenge, 
with worldwide rising prevalence. The Global 
Burden of Disease Study reported a preva-
lence of 251 million cases of COPD globally 
in 2016.3 It was projected to be the fourth 
leading cause of death worldwide by 2020.4 
Reductions in exacerbation and hospital-
isations are the outcomes rated as most 
important by patients with COPD.5 Effective 
delivery of evidence- based interventions for 
COPD—smoking cessation, influenza vacci-
nation, pulmonary rehabilitation, person-
alised inhaled therapy, home oxygen therapy 
(where indicated) and home non- invasive 
ventilation (NIV, where indicated)—has 
been shown to reduce exacerbation and 
hospital admission.6 There are considerable 
barriers to uptake and delivery of these inter-
ventions.7 This care quality gap particularly 
affects outcomes from COPD exacerbation. 
Exacerbation is the main driver of health-
care costs (estimated annual National Health 
Service (NHS) cost of managing COPD is 
Chronic obstructive pulmonary disease
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£1.9 billion.8 There is an urgent requirement for an 
innovation- based service redesign that can integrate care 
to deliver these evidence- based interventions and achieve 
reductions in COPD exacerbation and admissions.
Self- management also plays a key role in the treatment 
of COPD.9 Patients who can be successfully taught and 
supported with COPD self- management show a signifi-
cant reduction in COPD admissions.10 11 The process of 
establishing a multidisciplinary community respiratory 
team in NHS Greater Glasgow & Clyde (NHS GG&C), 
which supports self- management in patients identified 
acutely as being high risk of hospital admission, has been 
associated with reduction in hospital admission rates.12
While interventions should be developed for patients 
with all severities of COPD, it is logical to target imme-
diate efforts towards patients with ‘high- risk’ COPD, that 
is, those who are at most risk of exacerbation and hospital 
admissions. Established data indicate that patients with 
COPD who have had severe exacerbation (one requiring 
ED attendance or hospital admission) in the previous 
12 months and/or have persisting hypercapnic respira-
tory failure requiring home NIV fall into this high- risk 
group.6 13 Interventions proven in this group can then be 
rolled out (if cost- effective) to the lower risk groups of 
patients with COPD.
Digital service model
Pilot data from NHS GG&C have highlighted the poten-
tial for digital innovations to predict COPD outcomes and 
support treatment uptake. Using qualitative methods, 
Slevin et al highlighted patient acceptance to take an 
active role in self- management using digital health tech-
nology with the potential for healthcare professionals 
to provide meaningful preventative care.14 Web and 
smartphone- based apps have shown the capability to 
facilitate disease self- management and support uptake of 
interventions.15 16 Although patient- focused digital tools 
currently exist for COPD, there is a limited evidence base 
for their use, with evaluations mainly performed in isola-
tion and not integrated with established clinical services 
or statutory electronic health records (EHRs).
Most COPD management is currently based on a reac-
tive approach, and delays in recognising treatable oppor-
tunities underpin COPD care quality gaps. For example, 
patients with COPD exacerbation typically have symptom 
deterioration for 2 days before seeking assistance, and 
then a potential delay of 2–5 days in accessing clinical 
care.1 Several studies have indicated the ability of regu-
larly recorded patient- reported outcomes (PROs) and 
home NIV parameters to predict outcomes, including 
exacerbation and treatment success/failure in patients 
with COPD.17 18 Changes in activity measured by wear-
able devices have been shown to predict outcomes after 
COPD exacerbation.19 Currently, symptom diaries and 
other PRO questionnaires, activity, exercise and NIV data 
are obtained in routine practice in NHS GG&C. However, 
patient and clinician engagement is not consistent, data 
are not acquired systematically and are not often visible 
or actionable at key time points of patient–clinician inter-
action. These shortfalls, and the arising care quality gaps, 
could potentially be addressed by digitising this routine 
clinical care, improving the patient–clinician interface 
for data entry, and collating the acquired data.
Patient–clinician communication for COPD manage-
ment, including supporting self- management, is 
currently dependent on face- to- face scheduled consul-
tations, answer phone/email asynchronous messages 
from patient to clinician, and unstructured advocacy 
triggered or initiated communication from clinician to 
patient. These present several inefficiencies and risks. 
They could be overcome by digitalising the patient–clini-
cian messaging system to support scheduling, remote 
management and support COPD self- management.
Home NIV successfully improves admission- free 
survival in patients who have persisting hypercapnic respi-
ratory failure following life- threatening COPD exacerba-
tion, with a number needed to treat of seven patients.20 
NHS GG&C has successfully matched the outcomes from 
the HOT- HMV randomised clinical trial in our service 
adoption pilot delivering home NIV to eligible patients 
with COPD, using routinely available digital technolo-
gies (adaptive ‘auto- NIV’ modes, two- way remote moni-
toring via ResMed AirView platform).21 22 The challenge 
is to extend the evidence for this approach and obtain a 
service adoption playbook to enable this to be adapted 
and delivered at scale, by other clinical teams, within 
COPD integrated care.
Machine learning analysis and modelling based on 
available data shows significant promise in COPD predic-
tive management. Data available in patient’s EHR at 
triage assessment can robustly predict outcome (admis-
sion, length of stay) from severe COPD exacerbation.23 24 
The addition of physiology measurements to EHR data 
improves machine learning predictive model perfor-
mance in other clinical conditions.25 Further evaluation 
of these analytics and predictive modelling, in a compre-
hensive dataset including PROs, physiology data and clin-
ical events, is a logical step to determine their potential 
role in real- time or near real- time clinical use.
Objectives
Innovations which can empower patient self- management, 
facilitate integrated clinical care and support delivery 
of evidence- based treatment interventions are urgently 
required. In the Remote- Management of COPD: Eval-
uating the Implementation of Digital Innovation to 
Enable Routine Care (RECEIVER) trial, we propose to 
explore the implementation of a platform which digital-
ises these as additional—potentially assistive—compo-
nents alongside routine clinical care. In our endpoints, 
we will determine participant utilisation, clinical service 
impact and clinical outcomes, to evaluate the feasibility of 
this approach versus current standards of care. A digital 
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would also provide a foundation to explore the feasibility 
of approaches to predict outcomes and exacerbation in 
patients with COPD, to be tested in future prospective 
clinical and regulatory trials.
Our aims are to establish a digitalised service model for 
‘high- risk’ patients with COPD which will:
 ► Integrate current routine clinical care within a digitally 
enabled remote management service infrastructure.
 ► Enable delivery of remote management of COPD at 
scale within the NHS and other healthcare systems.
 ► Capture relevant routinely acquired PROs, contin-
uous physiology data and clinical event/episode data 
in a patient and clinician co- designed interface which 
enables engagement.
 ► Facilitate evolution from a reactive to a proactive and 
preventative COPD service model.
Digital service components
The digital service model will sit alongside routine clin-
ical care, aiming to assist and enhance current patient 
management. Key components of proposed digital service 
model for COPD are noted and summarised in figure 1. 
Tabulated information in online supplemental material 2 
outlines how the RECEIVER trial components would be 
used in addition to current routine clinical care.
The COPD digital service components being used in 
the RECEIVER trial are:
 ► Patient- facing web portal: this has been co- designed 
with patients and captures PROs and provides access 
to standard COPD self- management content. It also 
includes a messaging facility which can be patient or 
clinician initiated. Examples of visuals available on 
supporting website (https:// support. nhscopd. scot).
 ► Patient wearable device: Fitbit Charge 3 device (CE 
marked).
 ► Remotely monitored home NIV: provision of this is 
our current standard of care for patients with hyper-
capnic respiratory failure, using AirView NIV remote 
management platform (ResMed). We have inte-
grated our COPD digital service platform with the 
AirView platform, so that it acquires the NIV data 
unmodified for review where available. NIV therapy 
management will continue to be conducted through 
the AirView platform: the RECEIVER trial COPD 
platform is not used to modify or enhance patient 
NIV therapy.
Figure 1 RECEIVER Digital Service Components
COPD, chronic obstructive pulmonary disease; EHR, electronic health record; NHS GG&C, National Health Service 
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 ► User- designed clinical dashboard: presents integrated 
data with an aim of facilitating improvement in provi-
sion of guideline- based COPD care, and supporting 
COPD self- management.
 ► Patient–clinician asynchronous messaging: to support 
routine clinical care.
 ► NHS GG&C Azure cloud- based digital architecture: 
this provides and integrates the above services with 
existing NHS GG&C electronic healthcare systems. 
Diagram of digital architecture included in online 
supplemental material 3.
STUDY METHODS AND ANALYSIS
Study design
This study is a prospective observational cohort hybrid 
implementation and effectiveness study.26 It will be 
performed according to the UK Policy Framework for 
Health and Social Care Research (2020).27 The clinical 
intervention component is regarded as a phase IV adop-
tion study. Data visualisation to facilitate guideline- based 
care, supported self- management and home NIV are 
evidence- based COPD interventions.
In this study, we will evaluate the adoption of digitally 
integrated remote management service innovations to 
support routine clinical care. Implementation of these 
will be evaluated and the digital innovations will be iter-
ated to optimise them, based on user experience accrued 
during the study. We will acquire a consented dataset for 
trial endpoint analysis including exploratory machine 
learning- based predictive modelling. The machine 
learning analysis will also allow us to prioritise data inputs 
for follow- up study.
Secondary outcomes for the RECEIVER cohort will be 
compared with those from matched cohorts of patients 
acquired from the NHS GG&C SafeHaven dataset. Ethics 
approval is in place to access this large database of de- iden-
tified data, to establish a control cohort from a histor-
ical time series and a RECEIVER trial concurrent time 
series. These cohorts will be matched for demographics, 
COPD severity and hospital admission frequency with the 
RECEIVER cohort.
We will conduct a substudy of additional baseline and 
follow- up physiological measurements (oscillometry, 
parasternal electromyography (EMG), home pollution 
monitoring) in patients in whom it is feasible to obtain 
these during their hospital admission and/or hospital 
attendance alongside their routine clinical care.
Additionally, we will conduct a substudy of clinical 
users, with platform tracking analytics to measure clini-
cian time spent on the platform, and user experience 
data. Clinical team members involved in the delivery of 
patient support using the digital service will be eligible 
for inclusion and appropriate consent will be sought. 
The qualitative components will be acquired through 
semistructured group or 1:1 interviews conducted by 
trained members of the research team. Thematic analysis 
will be performed. Anonymised transcripts will be coded, 
and themes generated from the codes. Themes will be 
discussed within the research team to reach agreement 
and add rigour.
An overview of the study design is provided in figure 2.
Study population
People with high- risk COPD attending secondary care 
in the North and South Sectors of NHS GG&C will be 
screened for inclusion in this study.
Inclusion criteria:
 ► Confirmed diagnosis of COPD, established 
prescreening or at screening, defined as per Global 
Initiative for Chronic Obstructive Lung Disease 
(GOLD) 2020 guidelines.6
 ► Home NIV cohort: hypercapnic respiratory failure 
and/or sleep disordered breathing, meeting estab-
lished criteria for provision of home NIV.
 ► Exacerbation cohort: presentation within last 12 
months with severe or life- threatening exacerbation 
of COPD, defined as per GOLD 2020 guidelines.6
 ► Participant or close contact who has daily access to 
smartphone, tablet or home computer with internet 
access.
 ► Informed consent.
 ► >18 years of age.
Exclusion criteria:
 ► Inability to comprehend informed consent.
 ► Communication barrier precluding use of COPD 
digital service.
Sample size
Previous NHS GG&C studies,10 21 combined with internal 
audit data (showing that 80% of patients have direct or 
daily smartphone, tablet or web access), indicate that 
recruitment of 400 participants across a 12- month period 
is feasible, and likely to provide adequate data to conduct 
meaningful primary and secondary endpoint analyses.
An improvement in admission- free survival, with reduc-
tion in admissions by one per patient per year is projected, 
if support for provision of evidence- based COPD care is 
achieved by the service model. As the feasibility of an 
end- to- end digitalised service model for COPD has not 
yet been tested, and the service components will be 
adapted during the study, sample size power calculations 
and randomisation are not yet appropriate.
Screening and eligibility assessment
Participants will be identified from ED attendance, 
hospital admission or COPD multidisciplinary team 
referral. It is anticipated that the majority of participants 
will be identified and recruited during their index acute 
admission.
Review of focused medical history and lung function 
test results will be undertaken as part of screening eval-
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Informed consent
We will undertake informed consent with timing which 
is individualised to be least burdensome and most effi-
cient for participants. Written informed consent will 
be obtained by participant’s dated signature and dated 
signature of the person who presented and obtained the 
informed consent. The person who obtained the consent 
will be suitably qualified and experienced and have been 
given authority to do so by the principal investigator (PI).
In addition to consent for the clinical trial, General 
Data Protection Regulation (GDPR) consent for data 
sharing, data storage and tracking of web app activity 
is required, and this is sought within the COPD patient 
portal when participants complete initial sign- up to the 
service.
Withdrawal of subjects
Participants have the right to withdraw from the trial at 
any point, for any reason, without prejudice to future 
care. This is clearly stated at time of consent. The investi-
gator can also withdraw participants from the study inter-
vention in the event of protocol violations or if it was felt 
that involvement in the service was adding unnecessary 
burden or distress (eg, if participant was approaching 
end of life). Participant withdrawals will be included 
within the study analyses and reporting.
Participants may opt to limit the number of inter-
actions—for example, daily questionnaires, that they 
undergo, if these are burdensome. They may also request 
‘conventional’ scheduled face- to- face clinical review 
rather than remote managed review at any time point. 
Figure 2 RECEIVER Study Design
ACP, anticipatory care plan; CAT, chronic obstructive pulmonary disease assessment tool; COPD, chronic obstructive 
pulmonary disease; ED, emergency department; EHR, electronic health record; EMG, electromyography; FOT, forced 
oscillation technique; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GP, general practitioner; HTA, 
Health Technology Assessment; ML, machine learning; MRC, Medical Research Council dyspnea scales; NHS, 
National Health Service; NHS GG&C, National Health Service Greater Glasgow & Clyde; NIV, non- invasive ventilation; 
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This will be accommodated as outpatient or inpatient 
attendances, within routine clinical timescales as judged 
appropriate by the clinical team, in line with current 
service provision.
Participant identification
Study numbers will be assigned sequentially as each 
subject enters the study to ensure that study participant 
data are de- identified. Corresponding information will 
be recorded on the Case Report Form (CRF) by the 
investigator.
Source data
Source documents will include hospital medical records, 
clinical charts, laboratory and pharmacy records, radi-
ographs and correspondence. The patient web portal 
and clinician dashboard will be the source data for clin-
ical summary data, PROs, wearable and NIV physiology, 
patient–clinician messaging, clinical documentation and 
exacerbation/admission recording in participants. The 
clinician dashboard will also output this source data as 
structured report to NHS GG&C clinical portal (patient 
EHR).
Study data
Electronic data and COPD service digital architecture will 
be held within NHS GG&C e- health systems, with industry 
standard security and identity assurance processes. The 
core components of digital service will be on NHS GG&C 
Azure cloud tenancy, further ensuring security and iden-
tity assurance, and avoid need for data de- identification 
prior to machine learning analysis.
Data access will be password protected and accessible 
only by study investigators, with data management as per 
NHS GG&C and NHS Scotland data protection policies. 
Platform analytics will track user interactions and user 
data changes, to provide an audit trail for data integrity.
Subsequent assessments
Participants will be recruited into the digitalised service 
model over a 12- month period. Observation of secondary 
endpoints will be continued over the 12- month period 
following recruitment. Participants who are recruited will 
subsequently continue within the digital service model 
beyond the trial period, either until ongoing procure-
ment of the service infrastructure is established, or transi-
tion to alternative equivalent service model is completed.
Definition of end of trial
The end of trial will be when the last participant has 
completed follow- up, 12 months after recruitment.
Patient and public involvement
Patients and members of the public were involved 
throughout the planning and conduct of this research. 
The patient- facing web portal which forms the basis of 
the study was co- designed with patients with COPD and 
their carers. Semistructured interviews were conducted 
between patients and the development team to under-
stand patient experience of their condition, with feed-
back and adaptation of the application at each develop-
ment stage. Subsequent development of research ques-
tions and study design was informed by insights gained 
through these interactions.
Study limitations
We recognise that there is an inherent risk of bias and limi-
tations to using this type of study design with regard to the 
conclusions that can be drawn from the study outcomes. 
With this acknowledgement, our study seeks to explore 
the feasibility of using this digital service model within 
a real- world setting as opposed to providing evidence 
of definitive proof or utility. If feasibility is established, 
the format and experience gained from conducting this 
initial research will form the basis for future randomised 
studies.
DATA COLLECTION
Data collection by research team
EHR data
The following data will be obtained from EHRs held 
within NHS GG&C SafeHaven: demographic, coded diag-
nosis list, Charlson Comorbidity Index, Scottish Index 
of Multiple Deprivation quintile, medication history, 
laboratory results, lung function results, ED attendance, 
hospital admission, pulmonary rehabilitation attend-
ance data from 1 January 2010 onwards. These data will 
be presented for evaluation in a study machine learning 
analysis platform.
Baseline clinical data
The following data will be collated when the partici-
pant is enrolled and added to the clinical details form 
visible on the clinician dashboard: participant age, sex, 
smoking status, vaccination status, comorbidities, COPD 
exacerbation history, COPD medications, lung function 
results, key laboratory results including maximal eosin-
ophil count and modelled home pollution exposure 
(QCumber platform; NO2, O3, PM2.5, black carbon).
Participants who have not had contemporary spirom-
etry (standard lung function test) will have this repeated 
at the time of recruitment—this would be routine clinical 
care.
Follow-up clinical data
Smoking cessation, vaccination status, pulmonary reha-
bilitation, COPD comorbidity, COPD exacerbation 
history, COPD medications and other treatments, inhaler 
technique and narrative history will be updated at clin-


















es: first published as 10.1136/bm





Taylor A, et al. BMJ Open Resp Res 2021;8:e000905. doi:10.1136/bmjresp-2021-000905 7
Open access
A data feed from NHS GG&C Trakcare platform to 
RECEIVER Study COPD platform will present informa-
tion on hospital attendance and admissions.
Clinical episodes are also captured in the weekly PRO 
questionnaires, and manually inputted by the clinical 
team, when these are noted.
Accuracy of coding of clinical summary data and clin-
ical episodes will be reviewed in a proportion of recruited 
participants, by a respiratory physician working indepen-
dent of this study.
Physiology substudy
A subset of participants (where time and mode of pres-
entation allow) will be offered recruitment to the explor-
atory physiology substudy and have additional physiology 
measurements taken. These will comprise of oscillometry, 
parasternal EMG and home air pollution pack monitoring. 
Measurements from these may predict/associate with 
stability of COPD and clinical endpoints, and follow- up 
measurements may be taken at 3, 6, 9 and 12 months if 
feasible during study, alongside routine clinical care. The 
principal purpose of conducting these in this study is to 
report on feasibility within routine COPD assessment.
Data from PROs
Participants (or their family or carer) will complete PRO 
questionnaires in the patient web portal. Daily SMS 
and/or email notifications are provided as a prompt 
to complete these. There is support information in the 
associated website to assist participants with any difficul-
ties with the patient portal. Additional support will be 
provided by the clinical users if required.
Participants will complete symptom diary and COPD 
assessment tool (CAT) questionnaire daily. Medical 
Research Council dyspnea score (MRC) and health-
care episode questionnaires will be completed weekly. 
EQ- 5D- 5L generic quality of life questionnaire will be 
completed every 4 weeks. These questionnaires have been 
integrated to improve question flow and simplify the user 
experience. Questionnaire flow content is included in 
the online supplemental material 1.
PRO data are presented unmodified, in a ‘user- 
friendly’ format (co- designed with clinical users), in the 
clinician dashboard. These unmodified data will inform 
and enhance clinical encounters and patient–clinician 
communication.
Pilot user experience research shows that the daily 
PRO questions can be completed in ~70 s, with weekly 
questions taking an additional 90 s, and monthly generic 
quality of life questions taking an additional 5 min.
Specific permission for use of CAT questionnaire 
within this e- health system has been obtained. The use of 
other PROs is covered by available open licensing.
Wearable physiology measurement
Participants will be provided with a Fitbit Charge 3 wrist-
band wearable device, to monitor activity, sleep, heart 
rate and energy expenditure variables.
Wearable physiology results and device support instruc-
tions will be available to participants in the Fitbit app.
Wearable physiology results are presented unmodified 
in the clinical dashboard, to inform and enhance clinical 
encounters and patient–clinician communication.
Remote-monitored home NIV
Participants with severe COPD who have standard indi-
cations (persistent hypercapnia with PCO2 >7 kPa and/
or recurrent episodes of acute hypercapnic respiratory 
failure and/or COPD–obstructive sleep apnoea overlap 
and/or COPD with significant nocturnal hypoventila-
tion) are commenced on home NIV in NHS GG&C using 
Resmed Lumis 150 ST- A device as routine clinical care. 
Participants with significant obstructive sleep apnoea 
syndrome may be alternatively commenced or transi-
tioned to auto- titrating continuous positive airway pres-
sure (CPAP) using an AirSense-10 device. NIV initiation 
and optimisation will be conducted as per standard NHS 
GG&C clinical protocol. NIV data capture and device 
adjustment will be via ResMed AirView platform, again as 
routine clinical care.
AirView data will be acquired via an open application 
programming interface (API) to the COPD platform and 
presented in the clinical dashboard, to improve data visu-
alisation for NIV clinical management alongside PROs 
and wearable data, and to inform and enhance other clin-
ical encounters and patient–clinician communication.
Patient portal support materials, care plans and clinical 
decision support
The patient web portal will contain linked content to 
NHS GG&C smoking cessation, vaccination, inhaler 
therapy, pulmonary rehabilitation, breathing control and 
‘my lungs, my life’ COPD support literature, all to aid 
self- management.
The patient resource within the patient portal will 
contain a structured exacerbation self- management care 
plan. This is a digitalised version of the paper structured 
self- management plan without any change in format 
or content. Participants will be empowered to activate 
their own self- management plan or supported/directed 
to activate this with patient–clinician communication, 
as standard routine clinical care: the data access, visual-
isation and patient–clinician messaging facilities in this 
study will however enhance this.
Machine learning analysis and predictive modelling
These analyses will be conducted post hoc, using the clin-
ical data obtained from the RECEIVER trial COPD plat-
forms, alongside EHR data in historical and contempo-
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anticipation is that following analysis of the study data, 
we will be able to judge the feasibility and accuracy of 
using predictive model outputs at a service or individual 
patient level. This may lead to the subsequent develop-
ment and evaluation of artificial intelligence(AI)- based 
clinical decision support tools. Relevant clinical investiga-
tion/medical device trial(s) of these would be proposed 
and designed. The data from the RECEIVER trial would 
not be used directly to support clinical validation of any 
subsequently developed medical device.
Service model iterations
The components of the RECEIVER service model have 
been subject to pilot evaluation and pretrial patient and 
clinical user experience research. Service refinement 
based on the clinical user substudy experience research 
will continue during pretrial preparation and approval 
period. Iterations of the digital service content (eg, 
rationalisation of patient outcomes, modification or 
addition of self- management support materials) based 
on the adoption experience will be considered by the 
project steering group at three monthly intervals during 
the study. Where this iteration would result in a change in 
the clinical protocol, this will be submitted as an amend-
ment for consideration and regulatory approval before 
any change is implemented.
STUDY OUTCOME MEASURES
Primary and secondary endpoints for the RECEIVER 
Study are shown in table 1.
Primary endpoint measures
The proportion of participants who use the digital service 
model will be determined from screening versus recruit-
ment log, and with participant usage (PRO completion, 
wearable usage, home NIV usage and digital service 
contacts vs conventional healthcare contacts), monitored 
using consented platform tracking analytics. A target of 
submission of at least one PRO set per participant per 
week will be used to ascertain utilisation measures.
Secondary endpoint measures
Clinical events, hospital occupied bed days, treatment 
uptake, NIV usage and therapy, incidences of supported 
self- management and the impact of demographics on 
these will be captured within the digital service platform 
with data from weekly SafeHaven export, Trakcare real- 
time episode data feed and platform tracking analytics.
The process evaluation metrics for the digital service 
model will be captured by platform tracking analytics, 
project delivery process documentation and supplemen-
tary user experience research conducted as part of the 
digital service project delivery.
Machine learning- supported analysis of study dataset 
will be conducted post hoc.
Patient- centred outcomes will be captured within 
RECEIVER patient portal.
Qualitative user experience research will be under-
taken with a subgroup of participants to inform imple-
mentation strategy and will be presented as a descriptive 
summary. A sample of convenience will be taken from 
within the RECEIVER cohort. Semistructured inter-
views will be conducted, and thematic analysis will be 
performed. Interview transcripts will be coded, and the 
codes used to generate themes. Discussion of the themes 
within the research team will be conducted to ensure 
agreement and add rigour.
Cost analysis will be based on audited accounts for the 
RECEIVER innovation project delivery, combined with 
standard NHS tariffs, NHS Scotland medical/agenda 
for change salary scales and indirect costs from standard 
burden of COPD cost projections.
DATA MANAGEMENT
The study data file will be held in a locked cabinet in the 
Department of Respiratory Medicine, Queen Elizabeth 
University Hospital, Glasgow, with an electronic copy 
securely stored on the EDGE Clinical Research Manage-
ment System. All electronic data and COPD service 
digital architecture (including machine learning algo-
rithms) will be held within NHS GG&C e- health systems, 
with industry standard security and identity assurance 
processes. The core components of the digital service will 
be held within NHS GG&C Azure cloud tenancy, further 
ensuring security and identity assurance, and avoiding 
the need for data de- identification prior to machine 
learning analysis.
Data access will be password protected and accessible 
only by study investigators, with data management as 
per NHS GG&C and NHS Scotland data protection 
policies. Platform analytics will track user interactions 
and data changes, to provide an audit trail for data 
integrity.
At study completion, the comprehensive study 
dataset will be submitted for inclusion in NHS GG&C 
SafeHaven. This will allow (with appropriate SafeHaven 
standard operating proceedures (SOP) and Local 
Privacy and Advisory Committee (LPAC) application 
approvals) subsequent de- identified review of all study 
outcomes, reanalysis of the dataset, and contribution 
of the dataset to future COPD data linkage and other 
research work within NHS Scotland.
STATISTICS AND DATA ANALYSIS
Secondary outcomes in the RECEIVER observational 
cohort will be compared with matched retrospective 
data from de- identified linked datasets of historical 
control and contemporary control high- risk patients 
with COPD. These will comprise of patients identified 
from coding and admission data as having had severe 
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Table 1 RECEIVER primary and secondary endpoints
Primary endpoint




Clinical outcomes, comparing impact of digitally enabled remote management versus historical and 
contemporary SafeHaven cohorts:
 ► Clinical events: COPD exacerbation; unscheduled care contact (digital platform, COPD team visit, primary 
care, emergency department, hospital admission); mortality—COPD and non- COPD related.
 ► Hospital occupied bed days preceding and subsequent 12 months (adjusted time interval if survival <12 
months).
 ► Treatment uptake (where indicated): smoking cessation; pulmonary rehabilitation; vaccination; supported self- 
management; home oxygen; home NIV.
 ► NIV group: NIV usage, symptom change, NIV therapy parameters, blood gases during routine clinical care.
 ► Supported self- management: utilisation of self- management information (page views), number of 
exacerbation managed at home versus in hospital, number of rescue packs used in 12 months (captured 
through weekly PROs), utilisation of messaging (number of message threads), sputum microbiology (where 
available during routine clinical care), impact of patient activation measures (where measured during routine 
care).
 ► Impact of demographics, physiology and patient activation measures (where measured during routine care)—
deprivation category of area of residence, age and sex, number of previous admissions, smoking status, 
participation in pulmonary rehabilitation in previous 2 years; lung function measurements, modelled home air 
pollution exposure; EMG, oscillometry and home air pollution monitoring in subset of participants where this 
is carried out—on outcomes, clinical events and treatment uptake.
Clinical service outcomes for digital service model, remote- managed home NIV and supported self- 
management:
 ► Remote- managed home NIV: number, nature and complexity of NIV therapy reviews and interventions to 
provide.
 ► Supported self- management: number, nature and complexity of reviews and interventions to provide.
 ► Digitalised service model: user and developer time/cost required for development and modification of clinical 
dashboard; qualitative analysis (clinical user satisfaction and reflection on efficiency or additional workload); 
quantitative analysis (clinical dashboard utilisation tracking).
 ► Patient portal: user and developer time/cost required for development and modification of clinical dashboard; 
qualitative analysis (user satisfaction) and quantitative analysis (uptake, engagement with app and wearable, 
successful use of digital service vs bypass to conventional healthcare contacts).
Machine learning- supported exploratory analyses of associations and relative predictive importance of 
electronic health record, PROs, wearable physiology and NIV parameters:
 ► Associations between changes in PROs (MRC, CAT, symptom diary, and EQ- 5D- 5L questionnaires) with 
routine clinical care interventions, COPD exacerbation and other clinical events.
 ► Associations between changes in wearable monitoring parameters (activity, sleep, heart rate variability, energy 
expenditure, respiratory rate) with routine clinical care interventions, COPD exacerbation and other clinical 
events.
 ► Associations between changes in NIV- monitored parameters (usage, leak, airway pressures, respiratory rate, 
tidal volume, minute ventilation, inspiratory/expiratory ratio and detected respiratory events) with routine 
clinical care treatment interventions, COPD exacerbation and other clinical events.
 ► Associations between changes in clinical endpoints and relative importance plots of all remote management- 
acquired data (including EMG, oscillometry and home pollution monitoring exploratory endpoints in subgroup 
these measured on) to determine contribution of these to outcome prediction, and therefore value of these for 
future prospective study.
Patient- centred outcomes:
 ► Health- related quality of life (EQ- 5D- 5L) at baseline and monthly during study.
 ► Qualitative user research (planned subset of participants, convenience sample) with semistructured user 
experience interviews.
 ► Impact of patient activation (where this is measured at baseline and/or follow- up during routine clinical care) 
on enrolment and use of digital service model.
Healthcare cost analyses:
 ► Development and installation costs for digitalised service model for remote management of COPD.
 ► Recurring costs (clinical staffing, digital platform hosting, digital platform scheduled update and maintenance) 
for digital service model for remote management of COPD.
 ► Projected direct and indirect cost- savings (admission and unscheduled care reduction, travel, carer burden 
impact, clinical efficiency) of high- risk COPD with digitally enabled remote management, compared with 
previous service model.
CAT, Chronic obstructive pulmonary disease assessment tool; COPD, chronic obstructive pulmonary disease; EMG, Electromyography; 
MRC, Medical Research Council dyspnea scale; NIV, non- invasive ventilation; PROs, patient- reported outcomes; RECEIVER, Remote- 
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April 2019 (historical cohort) and between 1 July 2019 
and 30 June 2020, excluding participants enrolled in 
the RECEIVER Study (contemporary control). The 
historical control dataset will contribute to machine 
learning models development. Secondary outcome 
analysis will be separately compared between the 
RECEIVER cohort, historical cohort and contemporary 
control cohort. This component of the study is also 
separately registered with dataset access approval from 
NHS GG&C SafeHaven LPAC.
The clinical endpoint data will be reported as a 
proportion and 95% CI for that outcome, calculated 
by Kaplan- Meier method. Demographic data will be 
presented as mean and SDs, or medians and IQRs as 
appropriate. Correlation, t- test, analysis of variance 
and effect size analyses will be used as appropriate for 
secondary endpoint analysis, comparing results of clin-
ical endpoint and patient- centred outcomes with NIV 
therapy and supported self- management parameters.
Machine learning ensemble methods will be used to 
develop binary classification problems for patient risk. 
Precision, recall, accuracy and C- statistics of the receiver 
operating characteristic curve will be used to evaluate 
model performance.
RECEIVER TRIAL QUALITATIVE SUBSTUDY: PROTOCOL 
ADDITION AND AMENDMENT SEPTEMBER 2020
Following the outbreak of the COVID-19 pandemic, the 
digital service model established in the RECEIVER trial 
was adopted for routine clinical care in NHS GG&C. This 
was to mitigate for the anticipated COVID-19 impacts 
on routine COPD care, with concern about increased 
winter admission risks and continued requirement to 
maintain social distancing with vulnerable/shielding 
patients. Process for invitation and remote enrolment in 
the COPD digital service, via support website, has been 
established. People with COPD are enrolled following 
clinician referral or via invitations sent by Short Message 
Service (SMS) and letters to known patient cohorts.
Patient utilisation, clinical and service outcomes in 
this scale- up cohort will be evaluated in parallel with 
the data from the RECEIVER trial. These analyses will 
be conducted on de- identified data derived from NHS 
GG&C SafeHaven. There is separate ethics approval and 
protocol for these analyses.
It is relevant to gather user experience of the remote 
invitation and enrolment process to the digital service 
model and determine whether there are different expe-
riences based on the recruitment source (via clinical 
trial, via invitation and website registration, via clinician 
referral). A sample of convenience of people who have 
enrolled in the COPD digital service via this scale- up 
service model will be established by the clinical team. 
They will be approached by the clinical team via the 
digital service messaging interface. People expressing 
an interest in undertaking semistructured interviews 
about their service experience will be sent a RECEIVER 
substudy patient information sheet and consent form. 
These people would then be contacted by one of the 
study investigators with the consent form discussed and 
completed by telephone, avoiding COVID-19 context 
risk of face- to- face contact for vulnerable individuals. 
The consent form with investigator signature would be 
mailed to the participant. Semistructured interviews 
would then be scheduled and conducted by telephone 
or video call, using NHS GG&C Attend Anywhere 
platform.
ASSESSMENT OF SAFETY
The ‘RECEIVER’ digital service model is supporting 
rather than varying routine clinical care in people with 
COPD. Adverse device events and serious adverse events 
(ADEs and SAEs) will be captured within patient portal 
(eg, PRO question: have you had any hospital admis-
sions?) and within COPD platform (by Trakcare- derived 
clinical events) and provided as a summary report.
Where an SAE requires recording, full details including 
the nature of the event, start and stop dates, severity, rela-
tionship to research product and/or trial procedures, 
and the outcome of the event will be recorded in the 
participant’s medical notes and CRFs. These events will 
be monitored and followed up until satisfactory resolu-
tion and stabilisation.
Each SAE will be assessed to determine if related to the 
research procedures and expectedness where the event is 
related by the following definitions:
 ► Related: that is, it resulted from administration of 
study medicines or any of the research procedures.
 ► Expectedness of SAEs: is against the research proce-
dure events listed in study protocol as an expected 
occurrence.
Expected adverse events
In general, there is little additional risk to participants 
taking part in the study. However, the study aims to 
digitalise existing reporting pathways and therefore 
the potential exists for failures to occur within the soft-
ware used. Expected adverse events related to use of 
RECEIVER platform are as follows:
 ► Data connectivity issues: there may be issues with 
transfer of data from the participant to RECEIVER 
platform. Where these data relate to symptom diaries 
or Fitbit wearable data, there would be no impact on 
clinical care should the loss of data be temporary. 
However, in the event the data were permanently lost, 
this may impact on patient care.
 ► Messaging: there is a potential for messages sent from 
the participant to study staff (and vice versa) via the 
RECEIVER platform to be missed. There is also the 
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 ► Identity: there is the potential for data for one partic-
ipant to be allocated incorrectly to another partici-
pant due to errors within the RECEIVER platform 
software.
Adverse effects unrelated to the use of the RECEIVER 
platform are not considered reportable to the sponsor.
Exacerbation of COPD resulting in hospitalisation 
and potentially death is expected within the study popu-
lation. In addition, people with COPD may have other 
comorbid conditions. Events related to these conditions 
that meet the criteria of an SAE would also be considered 
expected. SAEs related to the participants’ underlying 
medical condition(s) that are not causally related to the 
RECEIVER platform are not reportable to the sponsor.
Safety reporting to sponsor
The following events are reportable to the sponsor:
 ► Any SAE that is causally related to the use of 
RECEIVER platform (serious adverse device effect—
SADE) regardless of expectedness.
 ► Any SAE that is related to the individual’s participa-
tion within the trial that is both related and unex-
pected but is not related to the use of the RECEIVER 
platform (related and unexpected SAEs—RUSAEs).
Study- related unexpected SAE must be reported to the 
Pharmacovigilance (PV) office immediately (within 24 
hours). The SAE form should be completed and signed 
by appropriately delegated staff. If necessary, a verbal 
report can be given by contacting the PV office. This must 
be followed up as soon as possible with a signed written 
(or electronic) report. If all of the required information 
is not available at the time of initial reporting, the PI (or 
designee) must ensure that any missing information is 
forwarded to the PV office as soon as this becomes avail-
able. The report should indicate that this information is 
follow- up information for a previously reported event.
The PV office will report all RUSAEs and unexpected 
SADEs (USADEs) to the ethics committee within 15 days 
of the PV office becoming aware of the event, via the 
‘report of SAE form’ for non- Clinical Trial of an Investi-
gational Medicinal Products (non- CTIMPs) published on 
the Health Research Authority website.
RUSAEs and USADEs will also be considered indi-
vidually by project steering group. Where appropriate, 
modifications (eg, additional patient alert notifications, 
additional clinical decision support notifications) to the 
RECEIVER platform will be made, in discussion with 
ethics committee and supported by protocol amendment.
Annual progress/safety report will be provided by the 
PI to the Research Ethics Committee(REC) and Research 
and Development (R&D) department.
Protocol amendments
Any change in the study protocol will require an amend-
ment. Any proposed protocol amendments will be 
initiated by the PI following discussion with the project 
steering group. Any required amendments forms will be 
submitted to the regulatory authority, ethics committee 
and sponsor. The PI and the project steering group 
will liaise with study sponsor to determine whether 
an amendment is non- substantial or substantial. All 
amended versions of the protocol will be signed by PI and 
sponsor representative. Before the amended protocol 
can be implemented, favourable opinion/approval must 
be sought from the original reviewing REC and R&D 
office(s).
DEVICE REGULATIONS
The COPD digital service patient and clinician appli-
cations are certified as class I under European Union 
Medical Device Regulations. The supplier (StormID) 
has a quality management system that is compliant with 
the requirements of International Standard BS EN ISO 
13485:2016.
ETHICS AND DISSEMINATION
This study will be carried out in accordance with the 
World Medical Association Declaration of Helsinki 
(1964) and its revisions (Tokyo (1975), Venice (1983), 
Hong Kong (1989), South Africa (1996) and Edinburgh 
(2000)).
Ethical approval for this clinical trial has been obtained 
from the West of Scotland Research Ethics Service. Partic-
ipants will only be allowed to enter the study once they 
have provided written informed consent. This PI will be 
responsible for updating the ethics committee of any new 
information related to the study.
Key results will be presented at local, national and 
international meetings, including those with patient 
representation. All data that are obtained will be 
submitted for publication to peer- reviewed journals. 
Principal and co- investigators will have access to all data 
analyses conducted by the project commercial partners 
(StormID), with investigators having full academic inde-
pendence for publication of results.
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Supplementary material 1: RECEIVER COPD Patient-web 
portal questionnaires  
  
COPD Patient App v5.0  
Patient Reported Outcome Flows  
  
Daily  
Symptom diary  
1. How are you feeling today?  
(1) Better than usual  
(2) Normal/usual  
(3) Worse than usual  
(4) Much worse than usual  
  
2. How is your breathing today?  
(1) Better than usual   
(2) Normal/usual  
(3) Worse than usual  
(4) Much worse than usual  
  
3. Do you have a cold or flu today?  
• Yes  
• No  
  
CAT (score /40)  





(5) I cough all the time  
  





(5) My chest is completely full of phlegm (mucus)  
  
Symptom diary additional questions  
How difficult is it to bring up phlegm when you cough?  
(1) Not difficult  
(2) A little difficult  
(3) Quite difficult  
(4) Very difficult  
  
What consistency is your phlegm?  
(1) Watery  
(2) Sticky liquid  
(3) Semi-solid  
(4) Solid  
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What colour is your phlegm?  
(1) White  
(2) Yellow  
(3) Green  
(4) Dark green  
  





(5) My chest feels very tight  
  





(5) When I walk up a hill or one flight of stairs I am very breathless  
  





(5) I am very limited doing activities at home  
  





(5) I am not at all confident leaving my home because of my lung condition  
  





(5) I don’t sleep soundly because of my lung condition  
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Weekly  
Symptom diary  
1. How are you feeling today?  
(1) Better than usual  
(2) Normal/usual  
(3) Worse than usual  
(4) Much worse than usual  
  
2. How is your breathing today?  
(1) Better than usual   
(2) Normal/usual  
(3) Worse than usual  
(4) Much worse than usual  
  
3. Do you have a cold or flu today?  
• Yes  
• No  
  
4. Have you increased your usual breathing treatment this week? (e.g. inhalers, 
nebulisers, tablets)  
• Yes  
• No  
  
5. Have you taken antibiotics this week?  
• Yes  
• No  
  
6. Have you visited your GP this week?  
• Yes  
• No  
  
7. Have you visited your hospital doctor this week?  
• Yes  
• No  
  
CAT (score /40) (For each of the following questions, please select the number that 
best describes you currently.)  





(5) I cough all the time  
  





(5) My chest is completely full of phlegm (mucus)  
  
Symptom diary additional questions  
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How difficult is it to bring up phlegm when you cough?  
• Not difficult  
• A little difficult  
• Quite difficult  
• Very difficult  
  
What consistency is your phlegm?  
• Watery  
• Sticky liquid  
• Semi-solid  
• Solid  
  
What colour is your phlegm?  
• White  
• Yellow  
• Green  
• Dark green  
  





(5) My chest feels very tight  
  





(5) When I walk up a hill or one flight of stairs I am very breathless  
  





(5) I am very limited doing activities at home  
  





(5) I am not at all confident leaving my home because of my lung condition  
  





(5) I don’t sleep soundly because of my lung condition  
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(5) I have no energy at all  
  
MRC (score /4)  
Please tick in the box that applies to you (one box only):  
1. I only get breathless with strenuous exercise  
1. I get short of breath when hurrying on the level or walking up and 
slight hill  
2. I walk slower than people of the same age on the level because of 
breathlessness or have to stop for breath when walking at my own pace on 
the level  
3. I stop for breath after walking about 100 yards or after a few minutes 
on the level  
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Every 4th week  
Symptom diary  
16. How are you feeling today?  
(1) Better than usual  
(2) Normal/usual  
(3) Worse than usual  
(4) Much worse than usual  
  
17. How is your breathing today?  
(1) Better than usual   
(2) Normal/usual  
(3) Worse than usual  
(4) Much worse than usual  
  
18. Do you have a cold or flu today?  
• Yes  
• No  
  
19. Have you increased your usual breathing treatment this week? (e.g. inhalers, 
nebulisers, tablets)  
• Yes  
• No  
  
20. "Have you taken a rescue pack or an acute course of antibiotics or steroids 
prescribed by a doctor for your COPD this week? This does not include long-
term antibiotics."?  
• Yes  
• No  
  
21. Have you visited your GP this week?  
• Yes  
• No  
  
22. Have you visited your hospital doctor this week?  
• Yes  
• No  
  
CAT (score /40) (For each of the following questions, please select the number that 
best describes you currently.)  





(5) I cough all the time  
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(5) My chest is completely full of phlegm (mucus)  
  
Symptom diary additional questions  
How difficult is it to bring up phlegm when you cough?  
• Not difficult  
• A little difficult  
• Quite difficult  
• Very difficult  
  
What consistency is your phlegm?  
• Watery  
• Sticky liquid  
• Semi-solid  
• Solid  
  
What colour is your phlegm?  
• White  
• Yellow  
• Green  
• Dark green  
  





(5) My chest feels very tight  
  





(5) When I walk up a hill or one flight of stairs I am very breathless  
  





(5) I am very limited doing activities at home  
  





(5) I am not at all confident leaving my home because of my lung condition  
  
29. (0) I sleep soundly  
(1)  
(2)  
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(3)  
(4)  
(5) I don’t sleep soundly because of my lung condition  
  





(5) I have no energy at all  
  
MRC (score /4)  
Please tick in the box that applies to you (one box only):  
1. I only get breathless with strenuous exercise  
1. I get short of breath when hurrying on the level or walking up and slight hill  
2. I walk slower than people of the same age on the level because of 
breathlessness or have to stop for breath when walking at my own pace on the 
level  
3. I stop for breath after walking about 100 yards or after a few minutes on the 
level  
4. I am too breathless to leave the house or I am breathless when dressing  
  
Every month we are asking some additional research questions to help us understand the 
impact of COPD on your quality of life.  These questions will take a further couple of 
minutes, but can be skipped if you prefer (with opt in/out click option)   
  
Quality of Life (EQ5D)  
Mobility  
• I have no problems in walking about  
• I have slight problems in walking about  
• I have moderate problems in walking about  
• I have severe problems in walking about  
• I am unable to walk about  
  
Self-care  
• I have no problems washing or dressing myself  
• I have slight problems washing or dressing myself  
• I have moderate problems washing or dressing myself  
• I have severe problems washing or dressing myself  
• I am unable to wash or dress myself  
  
Usual activities (e.g. work, study, housework, family or leisure activities)  
• I have no problems doing my usual activities  
• I have slight problems doing my usual activities  
• I have moderate problems doing my usual activities  
• I have severe problems doing my usual activities   
• I am unable to do my usual activities.  
  
Pain/discomfort  
• I have no pain or discomfort  
• I have slight pain or discomfort  
• I have moderate pain or discomfort  
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• I have severe pain or discomfort  
• I have extreme pain or discomfort  
  
Anxiety/depression  
• I am not anxious or depressed  
• I am slightly anxious or depressed  
• I am moderately anxious or depressed  
• I am severely anxious or depressed  
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Supplementary material 2: RECEIVER Trial – Digitalising Routine 
COPD care  
  
The components of the RECEIVER trial are a digitalisation of routine clinical care.  These 
components, including integrated care and supported self-management are as 
recommended in international consensus guidelines for COPD management: Global 
Obstructive Lung Disease (GOLD) guideline 2019.  
  
The table below summarises the routine clinical care currently available in NHS GGC and is 
shown alongside the trial schedule / study components that the digital service will add. 
These digital components are designed to assist and enhance current patient management 
but are not replacing current routine clinical care. 
  
  Routine clinical care  RECEIVER trial  
Symptom diary  CAT, MRC, symptom 
diary and generic-
QOL questionnaires completed on 
paper at home and/or at COPD 
clinical reviews.  Clinician 
aggregates and summarises data.  
CAT, MRC, symptom diary and 
generic-QOL questionnaires 
completed by 
patient in webform.    
Daily reminder text/email alert to 
complete.     
Data presented unmodified to 
clinician in COPD dashboard.  
Activity – exercise – 
sleep quantification  
Narrative history +/- exercise and 
sleep diary completed on 
paper.  Summary of patient Fitbit 
or other wearable device data 
reviewed when 
available.  Actigraphy carried out 
by clinical physiology team and 
results collated in pdf report.  
Patient provided RECEIVER study 
Fitbit.    
Fitbit data acquired via consent-
driven identity-assured API.    
Presented unmodified to clinician 
in COPD dashboard.   
Home NIV monitoring  Daily home NIV data available for 
clinician review in NHS 
GG&C Ehealth IG/security approved 
ResMed AirView remote-monitoring 
platform.  
Daily home NIV data acquired via 
consent-driving identity assured 
API from AirView remote-
monitoring platform.    
Presented unmodified to clinician 
in COPD dashboard.    
COPD self-management, 
generic  
Paper or digital information (British 
Lung Foundation, 
or MyLungsMyLife Scottish website 
developed by respiratory MCN) 
supports clinical explanations, 
including ‘traffic light’ system for 
recognising and managing 
exacerbations.  
RECEIVER patient dashboard and 
linked COPD support website 
contains content matching 
paper and digital information 
currently provided.  
COPD self-management, 
individualised   
Clinician documents for patient on 
paper (then in letter or other area 
of electronic health record) 
antibiotic and/or prednisolone dose 
Clinician documents in RECEIVER 
dashboard antibiotic and/or 
prednisolone dose for 
exacerbation.  This is visible at 
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for exacerbation.  Prescription 
provided.   
self-management section of 
patient dashboard, and exported 
to GP and GG&C electronic health 
record.  Prescription provided.  
Patient unscheduled 
contact with COPD 
clinical team  
Patient provided with leaflet and 
business card 
with answerphone/email for 
relevant clinical teams (hospital 
CNS, community resp team, clinical 
physiology team).   Standard 
written text and email auto-
reply on clinician availability and 
signposting for 
emergencies provided.  No admin 
support, ad-hoc approach to 
managing messages by clinical 
team.  
Patient can submit message via 
patient dashboard.    
Standard advice – identical to 
current clinical care – 
on clinician availability and 
signposting for emergencies 
provided on screen.   
Email and text message alerts 
patient to any new message from 
clinical team.   
Clinician messaging dashboard 
highlights new and unresolved 
messages.  RECEIVER project 
manager oversees and ensures 
appropriate response to patient, 
and any escalation.    
Scheduled patient 
reviews  
Appointments made via Trakcare or 
telephone/paper diary by clinical 
team.  Email and text message 
reminder alerts sent.  Telephone 
calls, text or email queries, 
videocalls (NHS attend anywhere) 
used in place of hospital or 
domiciliary attendance, when 
possible.   
Current routine-clinical care 
supplemented by clinician-patient 
messaging via RECEIVER 
dashboards.  E.g. messaging used 
for appointment scheduling, 
information gathering to add 
value-efficiency to telephone or 
face-face consultation.   
Clinical documentation  Paper notes (scanned to EHR), 
GG&C clinical portal clinical notes 
(in EHR), dictated-transcribed 
letters.  COPD shared 
documentation e-form in clinical 
portal (previously trakcare) q3-4 
2019.  Documentation siloed: often 
not visible/shared across primary-
secondary care split.  
Structured documentation and 
free text clinical notes in clinician 
RECEIVER dashboard.  Content 
matches COPD shared 
documentation clinical portal e-
form.  Clinical summary, clinical 
notes and anticipatory care plan 
exported as pdf from dashboard 
to EHR (SCI store and clinical 
portal), visible to all primary and 
secondary care team.  
Recording – recognition 
of clinical episodes / 
events  
Trakcare episodes and clinician-
dependant recognition and 
narrative documentation in EHR 
notes or letters.  
Trakcare episodes linked, and 
clinician recognition supported by 
symptom diary and messaging 
system.  Episodes-events logged 
unmodified in timeline in 
RECEIVER clinician dashboard.  
Patient data storage and 
management  
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Supplementary material 3: RECEIVER Trial – Data Storage in NHS 
GG&C Azure tenancy  
  
The working components of the COPD digital service are maintained within the NHS GG&C 
Lenus account.  The databases containing the patient data from the Receiver trial, and the 
historical and contemporary control cohort data from NHS GG&C SafeHaven is maintained 
in a separate account, with restricted access.  Planned analyses of these datasets is subject 
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